Privia Health Group (PRVA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.19
- Estimate
- $0.24
- Surprise
- -22.2%
- Revenue (period 2026-06-30)
- $632.6M
- Score today
- 6.1/10
Revenue source: xbrl.
How the report landed
Privia Health Group (PRVA) missed the $0.24 estimate with adjusted EPS of $0.19 — a large 22.2% shortfall.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PRVA Sell at 6.1/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -22.2% surprise compares with a +4.4% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Quality below floor (3.9 < 4.0)
- Value-trap signals (2/5): Material insider selling (24 sells, 0.17% of cap), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $21.64
- Price target
- $28.32
- Stop
- $20.42
- Upside to target
- +30.9%
- Reward-to-risk
- 2.5:1
The stock trades at 103.1× trailing but 20.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 84 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
PRVA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Health Information Services
- Market cap
- $2.77B
- P/E (fwd)
- 20.4
- P/E (ttm)
- 103.1
- 52-week range
- $18.91–$28.82
- Off 52-week high
- 24.9%
- RSI (14)
- 84
- Volume vs avg
- 0.49×
- Score today
- 6.1/10